Allarity Therapeutics (NASDAQ:ALLR) Issues Quarterly Earnings Results

Allarity Therapeutics (NASDAQ:ALLR) released its earnings results on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04, Zacks reports.

Allarity Therapeutics Price Performance

Shares of Allarity Therapeutics stock traded down $0.01 on Friday, hitting $1.18. The company had a trading volume of 199,149 shares, compared to its average volume of 246,352. Allarity Therapeutics has a twelve month low of $0.61 and a twelve month high of $2.35. The stock has a 50-day moving average of $1.51 and a 200-day moving average of $1.21. The firm has a market capitalization of $17.13 million, a P/E ratio of -0.15 and a beta of 0.24.

Analyst Ratings Changes

A number of brokerages have issued reports on ALLR. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised Allarity Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. Finally, Ascendiant Capital Markets lifted their price objective on Allarity Therapeutics from $9.00 to $9.25 and gave the stock a “buy” rating in a research note on Friday, September 26th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Allarity Therapeutics has a consensus rating of “Hold” and an average target price of $9.25.

Institutional Trading of Allarity Therapeutics

A number of institutional investors have recently modified their holdings of ALLR. Private Advisor Group LLC bought a new stake in Allarity Therapeutics in the 3rd quarter valued at approximately $441,000. XTX Topco Ltd acquired a new stake in shares of Allarity Therapeutics in the second quarter valued at approximately $51,000. Geode Capital Management LLC lifted its position in shares of Allarity Therapeutics by 49.3% in the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after purchasing an additional 16,729 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Allarity Therapeutics in the second quarter worth $27,000. 11.53% of the stock is currently owned by institutional investors.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.